Results of EXTRACT-PE Trial presented at Vascular InterVentional Advances (VIVA) Annual Meeting “The Indigo Aspiration System has demonstrated tremendous potential to address patients with clot in ...

Pulmonary embolism, or PE, is a deadly condition causing blood clots within a patient’s lungs that has grown in prevalence during the COVID-19 pandemic. The Indigo Aspiration System with Lightning 12 ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced U.S. Food and Drug Administration 510(k) clearance for ...

ALAMEDA, Calif., Nov. 10, 2020 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced a new partnership to develop solutions to enable ...

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the ...

Penumbra Inc. reported final results from its IDE trial of the Indigo Aspiration system at the Vascular Interventional Advances (VIVA) annual meeting in Las Vegas. The Alameda, Calif.-based company ...

Penumbra has completed subject enrolment in the multi-centre, randomised controlled trial, STORM-PE, which assesses the computer-assisted vacuum thrombectomy (CAVT) using the company’s Lightning Flash ...

Latest STRIKE-PE data show that computer assisted vacuum thrombectomy (CAVT) for the treatment of pulmonary embolism is safe and effective at reducing right heart strain; it also improved clinical and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Penumbra Inc. is conducting a study ...

ALAMEDA, Calif., Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical ...

Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results from its landmark STORM-PE randomized controlled trial. The study found that ...